BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,055 filers reported holding BAXTER INTL INC in Q2 2022. The put-call ratio across all filers is 1.57 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,924 | -20.2% | 103,975 | -3.7% | 1.40% | -23.7% |
| Q2 2023 | $4,918 | +13.0% | 107,951 | +0.6% | 1.83% | +13.4% |
| Q1 2023 | $4,354 | -19.0% | 107,352 | +1.9% | 1.62% | -24.4% |
| Q4 2022 | $5,372 | -99.9% | 105,395 | -0.7% | 2.14% | -20.2% |
| Q3 2022 | $5,719,000 | -11.7% | 106,187 | +5.3% | 2.68% | -3.8% |
| Q2 2022 | $6,477,000 | -18.9% | 100,845 | -2.1% | 2.78% | -3.8% |
| Q1 2022 | $7,991,000 | -9.0% | 103,052 | +0.8% | 2.89% | -5.2% |
| Q4 2021 | $8,777,000 | +11.0% | 102,243 | +4.0% | 3.05% | -1.0% |
| Q3 2021 | $7,906,000 | +1.8% | 98,301 | +1.9% | 3.09% | -1.4% |
| Q2 2021 | $7,768,000 | -7.1% | 96,491 | -2.7% | 3.13% | -26.4% |
| Q1 2021 | $8,365,000 | +9.8% | 99,181 | +4.4% | 4.25% | +4.4% |
| Q4 2020 | $7,621,000 | -0.9% | 94,977 | -0.7% | 4.07% | -10.9% |
| Q3 2020 | $7,690,000 | -4.4% | 95,627 | +2.4% | 4.57% | -13.9% |
| Q2 2020 | $8,042,000 | +6.6% | 93,405 | +0.6% | 5.31% | -21.1% |
| Q1 2020 | $7,541,000 | -1.4% | 92,885 | +1.5% | 6.73% | +18.8% |
| Q4 2019 | $7,650,000 | -4.0% | 91,489 | +0.4% | 5.67% | -7.2% |
| Q3 2019 | $7,971,000 | +6.2% | 91,132 | -0.6% | 6.10% | +1.3% |
| Q2 2019 | $7,508,000 | +3.5% | 91,673 | +2.8% | 6.03% | -2.3% |
| Q1 2019 | $7,251,000 | – | 89,172 | – | 6.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |